Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 18/20 | 0.51 |
| ▸ | BCL2 | P10415 | 14/20 | 0.43 |
| ▸ | BCL2L2 | Q92843 | 3/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22879234 | 0.88 | BCL2L1 (0.55) | BCL2L1BCL2BCL2L2MCL1 | |
| SCHEMBL10058369 | 0.87 | BCL2L1 (0.45) | BCL2L1BCL2BCL2L2MCL1 | |
| SCHEMBL29424556 | 0.84 | BCL2L1 (0.69) | BCL2L1BCL2BCL2L2MCL1 | |
| SCHEMBL15513466 | 0.84 | BCL2L1 (0.69) | BCL2L1BCL2BCL2L2MCL1 | |
| SCHEMBL2687025 | 0.84 | BCL2L1 (0.69) | BCL2L1BCL2BCL2L2MCL1 | |
| SCHEMBL10058370 | 0.82 | BCL2L1 (0.74) | BCL2L1BCL2 | |
| SCHEMBL10058364 | 0.78 | BCL2L1 (0.55) | BCL2L1BCL2 | |
| SCHEMBL4735312 | 0.78 | BCL2L1 (0.67) | BCL2L1BCL2BCL2L2MCL1 | |
| SCHEMBL3661881 | 0.77 | BCL2L1 (0.52) | BCL2L1BCL2BCL2L2MCL1 | |
| SCHEMBL26648000 | 0.75 | BCL2L1 (0.64) | BCL2L1BCL2BCL2L2MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168645-B2 | Arylsulfonamide compounds | GENENTECH, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | BCL2A1, BCL2, BAX | BCL2L1 5/4885BCL2 2/4885BCL2L2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.